Cabaletta’s Early Data Shows Potential for Treating Autoimmune Diseases
The company reported positive results in the first two patients who received its new CAR T therapy, CABA-201, which aims to treat the autoimmune diseases lupus and myositis.
Leading Life Sciences Program Highlights Regional Growth
John Swartley, PhD, MBA, provided the keynote address for a public program hosted by the Greater Philadelphia Chamber of Commerce that explored the growth of Greater Philadelphia's ecosystem.
Heirloom Builds Direct Carbon Capture Facility
Heirloom has announced the first phase of a decarbonization project to create two Direct Air Capture (DAC) facilities in North Western Louisiana,
Development of RNA Therapeutics Targets Neurological Diseases
The collaboration combines Ascidian's RNA exon editing technology with Roche's expertise in CNS delivery to create novel treatments for hard-to-treat neurological conditions.
Meet Jochi, the 2024 President’s Innovation Prize Winning Team Focused on Making Life Easier for Students with Learning Differences
The platform, called Jochi, which has further evolved since its conception in 2020, integrates easily into existing school systems and provides educators with tools to support these students.
EU Approves Expanded Use of Sobi’s Aspaveli® for Rare Blood Disorder
The European Commission has approved Sobi's drug Aspaveli® (pegcetacoplan) for broader use in adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.
Exyn Technologies Partners with Measur to Expand Canadian Footprint
Measur plans to bring Exyn's cutting-edge technologies like the Nexys 3D SLAM LiDAR payload system to market.
Cogwear to Open New Manufacturing Facility in St. Paul as it Continues to Expand
This new site will support the production of Cogwear’s second-generation brain-tracking headband, which offers real-time insights into various brain functions.
EnaChip Leverages Magnetics to PowerNext-Generation Microdevices
By electroplating specialized magnetic alloys directly onto semiconductor substrates, EnaChip offers innovative, high-performance, and cost-effective magnetic solutions.
Ascidian Therapeutics Announces First-Ever FDA approval of their Investigational New Drug (IND) ACDN-01, which Targets Rare Genetic Eye Diseases
Penn spinout Ascidian Therapeutics has achieved a significant milestone with the FDA's acceptance of their Investigational New Drug (IND) application for ACDN-01.